Cytek Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	167.63	299.5	364.62	166.12	30.24
Short-Term Investments	95.11	44.55	0	0	0
Cash & Cash Equivalents	262.74	344.05	364.62	166.12	30.24
Cash Growth	-23.63%	-5.64%	119.49%	449.34%	-
Receivables	55.93	48.86	29.76	16.99	17.15
Inventory	60.88	48.15	32.17	23.02	18.43
Other Current Assets	12.51	12.95	5.18	2.5	1.94
Total Current Assets	392.06	454.02	431.73	208.62	67.77
Property, Plant & Equipment	29.26	27.57	5.85	2.14	1.04
Goodwill and Intangibles	39.27	14.48	14.88	0.75	0.74
Other Long-Term Assets	33.87	23.42	10.84	8.47	0.82
Total Long-Term Assets	102.4	65.46	31.57	11.36	2.6
Total Assets	494.46	519.48	463.31	219.98	70.36
Accounts Payable	3.03	4.81	3.03	2.94	2.34
Deferred Revenue	37.83	26.11	16.87	7.12	4.97
Other Current Liabilities	15.37	18.13	13.28	16.47	13.73
Total Current Liabilities	56.23	49.04	33.18	26.54	21.04
Long-Term Debt	11.13	14.58	0	0	0
Other Long-Term Liabilities	34.04	30.31	24.74	15.15	16.37
Total Long-Term Liabilities	45.17	44.89	24.74	15.15	16.37
Total Liabilities	101.39	93.93	57.92	41.69	37.41
Total Debt	11.13	14.58	0	0	0
Debt Growth	-23.70%	-	-	-	-
Retained Earnings	-29.18	-17.03	-19.61	-22.61	-42.02
Comprehensive Income	-1.28	-0.7	0.9	0.07	-0.15
Shareholders' Equity	393.06	425.3	405.04	-16.03	-41.7
Net Cash / Debt	251.61	329.47	364.62	166.12	30.24
Net Cash / Debt Growth	-23.63%	-9.64%	119.49%	449.34%	-
Net Cash Per Share	1.86	2.38	4.47	5.10	1.44
Working Capital	335.83	404.98	398.55	182.09	46.73
Book Value Per Share	2.90	3.16	5.28	-0.55	-1.99

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).